Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMY572G)

Drug Name
Lu AF28996 Drug Info
Indication
Disease Entry ICD 11 Status REF
Parkinson disease 8A00.0 Phase 1 [1]
Cross-matching ID
TTD Drug ID
DMY572G

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Dopamine D1 receptor (D1R) TTZFYLI DRD1_HUMAN Stimulator [2]
Dopamine D2 receptor (D2R) TTEX248 DRD2_HUMAN Stimulator [2]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Dopamine D1 receptor (D1R) DTT DRD1 5.04 4.626 2.459 1.322
Dopamine D2 receptor (D2R) DTT DRD2 5.345 5.634 5.789 5.901
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Parkinson disease
ICD Disease Classification 8A00.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Dopamine D1 receptor (D1R) DTT DRD1 8.99E-01 -0.06 -0.3
Dopamine D2 receptor (D2R) DTT DRD2 2.20E-03 -0.51 -1.35
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT04291859) Interventional, Open-label, Exploratory Study, Investigating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Lu AF28996 in Patients With Parkinson's Disease. U.S.National Institutes of Health.
2 Clinical pipeline report, company report or official report of Lundbeck